Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron (Nasdaq: GERN), a commercial stage biopharmaceutical company, has announced the granting of non-statutory stock options to newly hired employees. The grants, made on October 16, 2024, include options to purchase a total of 680,220 shares of Geron common stock at an exercise price of $4.17 per share, matching the closing price on the grant date.
These stock options have a 10-year term and vest over four years, with 12.5% vesting after six months of employment and the remainder vesting in equal installments over the following 42 months. The grants were made as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN), un'azienda biofarmaceutica in fase commerciale, ha annunciato la concessione di opzioni su azioni non statutarie ai neoassunti. Le concessioni, effettuate il 16 ottobre 2024, comprendono opzioni per acquistare un totale di 680.220 azioni di azioni ordinarie di Geron a un prezzo di esercizio di $4,17 per azione, corrispondente al prezzo di chiusura alla data della concessione.
Queste opzioni su azioni hanno un termine di 10 anni e si maturano in quattro anni, con il 12,5% che matura dopo sei mesi di impiego e il rimanente che matura in rate uguali nel successivo periodo di 42 mesi. Le concessioni sono state effettuate come incentivi materiali all'occupazione in conformità con il Nasdaq Listing Rule 5635(c)(4) e sono soggette alle condizioni del Piano di Indennità del 2018 di Geron.
Geron (Nasdaq: GERN), una empresa biofarmacéutica en etapa comercial, ha anunciado la concesión de opciones sobre acciones no estatutarias a empleados recién contratados. Las concesiones, realizadas el 16 de octubre de 2024, incluyen opciones para comprar un total de 680,220 acciones de acciones comunes de Geron a un precio de ejercicio de $4.17 por acción, que coincide con el precio de cierre en la fecha de concesión.
Estas opciones sobre acciones tienen un plazo de 10 años y se adquieren durante cuatro años, con un 12.5% que se adquiere después de seis meses de empleo y el resto adquiriéndose en cuotas iguales durante los siguientes 42 meses. Las concesiones se realizaron como incentivos materiales para el empleo de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4) y están sujetas a los términos del Plan de Concesión de 2018 de Geron.
Geron (Nasdaq: GERN)은 상업 단계의 바이오 제약 회사로, 신입 직원에게 비법정 주식 옵션을 부여한다고 발표했습니다. 2024년 10월 16일에 이루어진 이번 부여에는 680,220 주의 Geron 보통주를 주당 $4.17에 구매할 수 있는 옵션이 포함되어 있으며, 이는 부여일의 종가와 일치합니다.
이 주식 옵션은 10년의 기간을 가지며, 4년에 걸쳐 권리가 발생합니다. 6개월 근무 후 12.5%의 권리가 발생하며, 나머지는 다음 42개월 동안 동일한 금액으로 발생합니다. 이러한 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용을 유도하기 위한 실질적인 유인으로 이루어졌으며, Geron의 2018년 유인 보상 계획의 조건을 따릅니다.
Geron (Nasdaq: GERN), une entreprise biopharmaceutique en phase commerciale, a annoncé l'octroi d'options sur actions non statutaires à de nouveaux employés. Les octrois, effectués le 16 octobre 2024, comprennent des options d'achat d'un total de 680 220 actions ordinaires de Geron à un prix d'exercice de 4,17 $ par action, correspondant au prix de clôture à la date d'octroi.
Ces options sur actions ont une durée de 10 ans et sont acquises sur quatre ans, avec 12,5 % acquises après six mois d'emploi et le reste acquérant des droits en versements égaux sur les 42 mois suivants. Ces octrois ont été réalisés comme des incitations matérielles à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4) et sont soumis aux conditions du Plan d'Indemnisation 2018 de Geron.
Geron (Nasdaq: GERN), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, hat die Gewährung von nicht gesetzlichen Aktienoptionen an neu eingestellte Mitarbeiter bekannt gegeben. Die Gewährungen, die am 16. Oktober 2024 vorgenommen wurden, beinhalten Optionen zum Kauf von insgesamt 680.220 Aktien des Stammkapitals von Geron zu einem Ausübungspreis von 4,17 USD pro Aktie, was dem Schlusskurs am Tag der Gewährung entspricht.
Diese Aktienoptionen haben eine Laufzeit von 10 Jahren und erwerben sich über einen Zeitraum von vier Jahren, wobei 12,5 % nach sechs Monaten Beschäftigung erworben werden und der Rest in gleichen Raten über die folgenden 42 Monate erworben wird. Die Gewährungen wurden als materielle Anreize für die Beschäftigung gemäß der Nasdaq Listing Regel 5635(c)(4) vorgenommen und unterliegen den Bedingungen des Gerons 2018 Inducement Award Plans.
- Geron is attracting new talent by offering stock options as inducements
- The company is expanding its workforce, potentially indicating growth
- Granting of stock options may lead to potential dilution for existing shareholders
The stock options were granted on October 16, 2024, at an exercise price of
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017555168/en/
Aron Feingold
Vice President, Investor Relations and Corporate Communications
Kristen Kelleher
Associate Director, Investor Relations and Corporate Communications
investor@geron.com
media@geron.com
Source: Geron Corporation
FAQ
How many shares of Geron (GERN) stock options were granted to new employees?
What is the exercise price for the Geron (GERN) stock options granted on October 16, 2024?
What is the vesting schedule for the Geron (GERN) stock options granted to new employees?
Under which Nasdaq rule were the Geron (GERN) stock options granted?
